MA56440A - Dérivé de tétrahydroisoquinoléine substitué utilisé en tant que modulateur allostérique positif d1 - Google Patents

Dérivé de tétrahydroisoquinoléine substitué utilisé en tant que modulateur allostérique positif d1

Info

Publication number
MA56440A
MA56440A MA056440A MA56440A MA56440A MA 56440 A MA56440 A MA 56440A MA 056440 A MA056440 A MA 056440A MA 56440 A MA56440 A MA 56440A MA 56440 A MA56440 A MA 56440A
Authority
MA
Morocco
Prior art keywords
positive allosteric
derivative used
allosteric modulator
tetrahydroisoquinoline derivative
substituted tetrahydroisoquinoline
Prior art date
Application number
MA056440A
Other languages
English (en)
Inventor
Ali Ates
David Skolc
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of MA56440A publication Critical patent/MA56440A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MA056440A 2019-07-01 2020-06-29 Dérivé de tétrahydroisoquinoléine substitué utilisé en tant que modulateur allostérique positif d1 MA56440A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19183643 2019-07-01

Publications (1)

Publication Number Publication Date
MA56440A true MA56440A (fr) 2022-05-11

Family

ID=67137843

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056440A MA56440A (fr) 2019-07-01 2020-06-29 Dérivé de tétrahydroisoquinoléine substitué utilisé en tant que modulateur allostérique positif d1

Country Status (23)

Country Link
US (1) US20220259179A1 (fr)
EP (1) EP3993794A1 (fr)
JP (1) JP7510444B2 (fr)
KR (1) KR20220029686A (fr)
CN (2) CN117700395A (fr)
AR (1) AR119318A1 (fr)
AU (1) AU2020299953B2 (fr)
BR (1) BR112021022378A2 (fr)
CA (1) CA3139571A1 (fr)
CL (1) CL2021002946A1 (fr)
CO (1) CO2021018155A2 (fr)
EC (1) ECSP21093559A (fr)
IL (2) IL319939A (fr)
MA (1) MA56440A (fr)
MX (2) MX2021015873A (fr)
MY (1) MY210361A (fr)
PE (1) PE20221020A1 (fr)
PH (1) PH12021552825A1 (fr)
SA (1) SA521431279B1 (fr)
SG (1) SG11202112537YA (fr)
TW (2) TW202537959A (fr)
WO (1) WO2021001288A1 (fr)
ZA (1) ZA202109193B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4200280T3 (pl) 2020-10-07 2024-05-20 Eli Lilly And Company Pochodne fenylo-3,4-dihydroizochinolin-2(1h)-ylo-etan-1-onu jako dodatnie modulatory allosteryczne receptora dopaminy d1
CA3202993A1 (fr) 2020-12-18 2022-06-23 UCB Biopharma SRL Derive de tetrahydroisoquinoleine substitue utilise en tant que modulateur allosterique d1-positif
JP7734193B2 (ja) 2020-12-18 2025-09-04 ユーシービー バイオファルマ エスアールエル ２－（３，５－ジクロロ－１－メチル－インダゾール－４－イル）－１－［（１ｓ，３ｒ）－３－（ヒドロキシメチル）－５－（１－ヒドロキシ－１－メチル－エチル）－１－メチル－３，４－ジヒドロ－１ｈ－イソキノリン－２－イル］エタノンのプロドラッグ
KR20230121867A (ko) * 2020-12-18 2023-08-21 유씨비 바이오파마 에스알엘 무정형 고체 분산체
JP2024509272A (ja) * 2021-03-09 2024-02-29 イーライ リリー アンド カンパニー パーキンソン病の進行を減速させるためのメビダレン及び他のｄ１ポジティブアロステリック調節因子の使用
WO2026022198A1 (fr) 2024-07-25 2026-01-29 UCB Biopharma SRL Procédé de préparation de 2-(3,5-dichloro-1-méthyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxyméthyl)-5-(1-hydroxy-1-méthyl-éthyl)-1-méthyl-3,4-dihydro-1h-isoquinoléin-2-yl]éthanone monohydrate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0808525A2 (pt) 2007-03-01 2014-08-19 Janssen Pharmaceutica Nv Compostos de tetraidroisoquinolina como moduladors do receptor de histamina h3
KR101284796B1 (ko) 2011-10-05 2013-07-10 (주)포인트엔지니어링 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
BR112017007123B1 (pt) 2014-10-08 2023-01-31 Ucb Biopharma Sprl Composto representado pela fórmula (i-a), ou um seu sal farmaceuticamente aceitável, uso de um composto de fórmula (ia) e composição farmacêutica
WO2017178377A1 (fr) * 2016-04-13 2017-10-19 Ucb Biopharma Sprl Dérivés de tétrahydroisoquinoléine
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑

Also Published As

Publication number Publication date
EP3993794A1 (fr) 2022-05-11
PE20221020A1 (es) 2022-06-16
IL289314A (en) 2022-02-01
IL289314B2 (en) 2025-09-01
IL289314B1 (en) 2025-05-01
CO2021018155A2 (es) 2022-01-17
CN113993857A (zh) 2022-01-28
PH12021552825A1 (en) 2022-10-03
MY210361A (en) 2025-09-13
US20220259179A1 (en) 2022-08-18
ZA202109193B (en) 2023-11-29
CA3139571A1 (fr) 2021-01-07
TW202537959A (zh) 2025-10-01
CN117700395A (zh) 2024-03-15
BR112021022378A2 (pt) 2022-03-08
WO2021001288A9 (fr) 2021-09-02
IL319939A (en) 2025-05-01
CL2021002946A1 (es) 2022-07-15
AU2020299953B2 (en) 2025-06-05
TWI875776B (zh) 2025-03-11
ECSP21093559A (es) 2022-02-25
MX2024015493A (es) 2025-02-10
MX2021015873A (es) 2022-02-03
WO2021001288A1 (fr) 2021-01-07
JP2022539152A (ja) 2022-09-07
SG11202112537YA (en) 2021-12-30
CN113993857B (zh) 2024-01-02
AU2020299953A1 (en) 2022-01-06
AR119318A1 (es) 2021-12-09
JP7510444B2 (ja) 2024-07-03
TW202115010A (zh) 2021-04-16
KR20220029686A (ko) 2022-03-08
SA521431279B1 (ar) 2024-01-09

Similar Documents

Publication Publication Date Title
MA56440A (fr) Dérivé de tétrahydroisoquinoléine substitué utilisé en tant que modulateur allostérique positif d1
EP3906026A4 (fr) Inhibiteurs irréversibles de l'interaction ménine-mll
DK3774791T3 (da) Heterocykliske forbindelser som immunmodulatorer
EP3761790A4 (fr) Picolinamides en tant que fongicides
DK3743406T3 (da) Tmem16a modulatorer
IL281492A (en) Modulators of pnpla3 expression
HUE062866T2 (hu) TREX-1 modulátorok
EP3899024A4 (fr) Modulateurs de l'expression de hsd17b13
HUE065501T2 (hu) A KEAP1-NRF2 protein-protein kölcsönhatás inhibitorok
EP3675849A4 (fr) Modulateurs de tétrahydrocannabinol
EP3934474C0 (fr) Système de fermeture réutilisable
IL284061A (en) Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
EP4010529C0 (fr) Papier de sécurité
EP3758704A4 (fr) Modulateurs de l'expression d'irf4
EP3924762A4 (fr) Boîtier d'épissage
MA44772A (fr) 6-aminopyridine-3-yl thiazoles utilisés en tant que modulateurs de ror t
EP4025957C0 (fr) Modulateur électro-optique
EP3779540A4 (fr) Modulateur optique
EP3831810A4 (fr) Dérivé de benzène
DK3767115T3 (da) Rillet pakskive
MA56445A (fr) Dérivé de tétrahydroisoquinoléine substitué utilisé comme modulateur allostérique positif de d1
EP3848365A4 (fr) Inhibiteur de trk utilisés en tant que médicament anticancéreux
EP3999354C0 (fr) Objet anti-contrefaçon
MA53898A (fr) Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation en tant que médicament
DK3774796T3 (da) Et substitueret oxopyridinderivat